Evidence map›Paper›PMID 40407991›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Beyond memory: leveraging CSF biomarkers in all MCI patients ahead of anti-amyloid therapies.

Martina Poli, Chiara Giuseppina Bonomi, Luca Tretola, Marta Rosa, Martina Gaia Di Donna, Alessandra Moreschini, Marzia Nuccetelli, Sergio Bernardini, Nicola Biagio Mercuri, Alessandro Martorana and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Martina PoliMemory Clinic and Neurodegenerative Dementia Research Unit, University of Rome Tor Vergata, Rome, Italy.
Chiara Giuseppina BonomiMemory Clinic and Neurodegenerative Dementia Research Unit, University of Rome Tor Vergata, Rome, Italy.
Luca TretolaMemory Clinic and Neurodegenerative Dementia Research Unit, University of Rome Tor Vergata, Rome, Italy.
Marta RosaMemory Clinic and Neurodegenerative Dementia Research Unit, University of Rome Tor Vergata, Rome, Italy.
Martina Gaia Di DonnaMemory Clinic and Neurodegenerative Dementia Research Unit, University of Rome Tor Vergata, Rome, Italy.
Alessandra MoreschiniMemory Clinic and Neurodegenerative Dementia Research Unit, University of Rome Tor Vergata, Rome, Italy.
Marzia NuccetelliDivision of Clinical Biochemistry and Clinical Molecular Biology, University of Rome Tor Vergata, Rome, Italy.
Sergio BernardiniDivision of Clinical Biochemistry and Clinical Molecular Biology, University of Rome Tor Vergata, Rome, Italy.
Nicola Biagio MercuriNeurology Unit, Policlinico Tor Vergata, University of Rome Tor Vergata, Rome, Italy.
Alessandro MartoranaMemory Clinic and Neurodegenerative Dementia Research Unit, University of Rome Tor Vergata, Rome, Italy. martorana@med.uniroma2.it.ORCID http://orcid.org/0000-0001-8456-4169
Caterina MottaMemory Clinic and Neurodegenerative Dementia Research Unit, University of Rome Tor Vergata, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the era of anti-amyloid (Aβ) monoclonal antibodies (AMABs), with the recent marketing authorization granted for lecanemab by European Medicines Agency (EMA), randomized clinical trial selection criteria typically include memory impairment detection. In a cohort of patients with Mild Cognitive Impairment (MCI), we observed a non-biunivocal relationship between Aβ pathology and memory deficits, with Aβ pathology present even in patients with atypical clinical presentations. This suggests that using MCI, regardless of the presence of memory impairment, as the sole general criteria along with amyloid pathology biomarkers, could expand the pool of eligible patients. The presence of patients with non-amnestic MCI and underlying Alzheimer's Disease (AD) pathology makes a timely biomarker-based diagnosis necessary, as they may be considered eligible for treatment with AMABs according to current prescribing guidelines, even in the absence of memory impairment. However, it remains unclear whether, for such patients, the potential efficacy of AMABs actually outweighs the risks associated with treatment.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesCognitive DysfunctionMemory DisordersAgedBiomarkersHumansAmyloid beta-PeptidesBiomarkersAlzheimer’s diseaseAnti-amyloid monoclonal antibodiesBiomarkersMild cognitive impairment

Identifiers

PMID40407991
PMCPMC12394294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.